Humalog

Humalog is a rapid‑acting insulin analog whose active ingredient is insulin lispro, supplied in a standard subcutaneous injectable form for prescription use in the European market. It is designed to quickly lower blood glucose levels in patients with diabetes mellitus and is classified as a prescription‑only antidiabetic agent.

Humalog is prescribed to manage blood glucose in diabetes mellitus when rapid insulin action is required. It is commonly used in the following situations: - Mealtime (prandial) insulin coverage for type 1 diabetes. - Mealtime (prandial) insulin coverage for type 2 diabetes. - Supplemental insulin for patients on basal insulin regimens. - Adjustment of insulin dose during illness or stress. - Use in insulin pump therapy when rapid‑acting insulin is needed.

Adverse reactions to Humalog can vary in frequency and severity.

Common: - Mild hypoglycemia (low blood sugar). - Injection site redness, swelling, or itching. - Lipodystrophy at the injection site. - Transient weight gain. - Headache.

Serious: - Severe hypoglycemia requiring assistance. - Allergic reactions such as urticaria or angioedema. - Anaphylactic shock (rare). - Persistent hyperglycemia due to insulin resistance. - Acute metabolic acidosis (euglycemic ketoacidosis).

When using Humalog, several safety considerations should be observed: - Monitor blood glucose frequently, especially before meals and at bedtime. - Adjust dose in renal or hepatic impairment to avoid hypoglycemia. - Educate patients on recognizing and treating hypoglycemia promptly. - Use caution during pregnancy; benefits must outweigh potential risks. - Store the product according to label instructions to maintain potency. - Do not use after the expiration date or if the solution is discolored. - Consult a healthcare professional before switching insulin types.

Humalog may interact with other substances that affect glucose metabolism.

Avoid: - Concurrent use of other rapid‑acting insulins without proper dose adjustment. - Administration of high‑dose beta‑blockers that mask hypoglycemia symptoms.

Use with caution: - Oral antidiabetic agents (e.g., sulfonylureas, meglitinides) that increase hypoglycemia risk. - Alcohol consumption, which can potentiate insulin’s glucose‑lowering effect. - Corticosteroids or thiazide diuretics that raise blood glucose levels. - Beta‑agonists (e.g., albuterol) that may increase glucose levels. - Thyroid hormones that can alter insulin requirements.